The study addresses the impact of amino acid infusion in the early post-transplant period on graft function and the incidence of post-transplant complications.
Adult patients (≥18 years) undergoing deceased or living donor kidney transplantation
First-time kidney transplant recipients
No known allergy or contraindication to amino acids
Stable hemodynamic status post-transplant
Patients requiring immediate dialysis post-transplant
Multi-organ transplant recipients
Severe hepatic dysfunction (Child-Pugh C)
Uncontrolled infection or sepsis
Parallel
Infusion Therapy
DrugInfusion of amino acids once daily - dose 1g/kg, maximum 100 g daily for 3 consecutive days starting D1 after kidney transplantation procedure
Saline solution infusion
DrugInfusion of saline solution a s standard rehydration therapy after kidney transplantation
Improving graft function 3 months after kidney transplantation
Investigators assume infusion of amino acids will improve eGFR in the intervals: 7 days / 14 days / 30 days / 90 days after kidney transplantation.
Decrease of the biopsy proven acute rejection incidence
Investigators assume the infusion of amino acids will decrease the incidence of biopsy proven acute rejection in 3rd month after kidney transplantation
Improving levels of total proteins and albumin
Investigators assume infusion amino acids will improve levels of total proteins and albumin.
Lipid profile improvement
Investigators assume infusion amino acids will improve levels of total cholesterol, triacyglycerides and LDL-cholesterol.
Decreasing the incidence of delayed graft function
Investigators assume the infusion of amino acids will decrease the incidence of DGF defined as a need for hemodialysis first week (7 days) after kidney transplantation.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
